# AGAP5

## Overview
AGAP5 is a gene that encodes the protein ArfGAP with GTPase domain, ankyrin repeat, and PH domain 5, which is involved in various cellular processes, including membrane trafficking and cytoskeletal organization. This protein is categorized as a GTPase-activating protein (GAP) due to its role in activating GTPase activity. The protein's structure includes an ADP-ribosylation factor (Arf) GAP domain, ankyrin repeat (ANK) domains, and a pleckstrin homology (PH) domain, which are essential for its function. AGAP5 has been implicated in cardiac development and maintenance, with associations to heart failure risk loci and cardiovascular diseases such as atrial fibrillation (Nguyen2023Genetic; Patel2023Genomic). Despite its recognized roles, the precise functions of AGAP5 in normal human physiology are not fully elucidated.

## Function
The AGAP5 gene encodes a protein that plays a significant role in cellular processes such as membrane trafficking and cytoskeletal organization. The protein contains an ADP-ribosylation factor (Arf) GAP domain, ankyrin repeat (ANK) domains, and a pleckstrin homology (PH) domain, which are crucial for its function as a GTPase activity activator (Nguyen2023Genetic). The PH domain serves as a critical protein-binding site necessary for catalyzing GTPase activity, and its interaction with the Arf GAP domain is essential for activating AGAP5 function. Arfs, which are part of the Ras small GTPases subfamily, rely on GTP exchange factors for activation, as they lack intrinsic GTPase activities (Nguyen2023Genetic).

AGAP5 is involved in cardiac development and sarcomere maintenance, as indicated by its association with heart failure risk loci (Patel2023Genomic). The gene is also linked to cardiovascular diseases, including atrial fibrillation and heart failure, through its involvement in cytoskeleton signaling and cardiac function (Patel2023Genomic). Despite these insights, the specific function of AGAP5 in healthy human cells remains less detailed in the available literature.

## Interactions



## References


[1. (Nguyen2023Genetic) Quynh-Anh Nguyen, Wan-Hsuan Chou, Mao-Chih Hsieh, Che-Mai Chang, Wei-Tzu Luo, Yu-Ting Tai, and Wei-Chiao Chang. Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy. Frontiers in Oncology, April 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1054406, doi:10.3389/fonc.2023.1054406. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1054406)

[2. (Patel2023Genomic) Kush Ketan Patel, Cynthia Venkatesan, Habiba Abdelhalim, Saman Zeeshan, Yuichiro Arima, Suvi Linna-Kuosmanen, and Zeeshan Ahmed. Genomic approaches to identify and investigate genes associated with atrial fibrillation and heart failure susceptibility. Human Genomics, June 2023. URL: http://dx.doi.org/10.1186/s40246-023-00498-0, doi:10.1186/s40246-023-00498-0. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-023-00498-0)